Header
Ihr Suchergebnis
Sie recherchieren derzeit unangemeldet.Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Kappler M.
In der Rubrik Zeitschriften haben wir 1 Beitrag für Sie gefunden
-
MerkenFacility design to ensure European compliance for oligonucleotide manufacturing
Rubrik: Biotechnologie
(Treffer aus Tech4Pharma, Nr. 04, Seite 212 (2024))
Facility design to ensure European compliance for oligonucleotide manufacturing / Kappler • Oligonucleotide manufacturing · Kappler M · CRB Germany GmbH, Böblingen
Oligonucleotides Facility design Hazardous materials RNA therapeutics Environmental regulations Globally, the market for oligonucleotide therapeutics is estimated to grow rapidly [ 1 ], reflected by the hundreds of oligonucleotide therapeutics in clinical trials. There has been a significant increase in regulatory approvals of oligonucleotide therapies since the first one received market authorization in 2016. By the end of 2022, there were close to 80 more applications in phase 1 and phase 2 trials [ 2 ]. Based on a 2021 survey of industry experts, among those whose company pipeline contains oligonucleotide therapy products, a doubling of manufacturing capacity was expected in the next ...
